Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoziborole DDI Study with Midazolam and Dextromethorphan
NCT05947604Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acoziborole in African trypanosomiasis (HAT), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam, Maximum Plasma Concentration (Cmax) of Dextromethorphan and 4 more. Started Feb 2023; status: completed.
02
Drugs
acoziborole
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on NCT05947604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947604.